ABMC To Manufacture Test For Syphilis
The HDS EXPRESS generates results in approximately 15-20 minutes, incorporating a simple, pre-marked series of lines on the sample pad, which is used to clearly identify when sufficient blood has been taken up onto the pad. This feature aids in eliminating guesswork and ensures reliable, repeatable test results. The product will not be sold in the United States until such time as the appropriate regulatory approval is received rather, HDS will focus its efforts on developing markets outside of the United States where this pandemic is most prevalent.
The World Health Organization (WHO) estimates that 40 million cases of Syphilis are reported every year throughout the world, 12 million of these being new cases. Approximately 36,000 cases are reported annually by health officials in the United States. Syphilis is a curable infection that is sexually transmitted and can also be passed on from a mother to her fetus during pregnancy. If left untreated, syphilis can cause serious consequences such as neurological disorders and stroke, and in pregnant women, stillbirth, prematurity and neonatal deaths. Many countries, especially those in Africa, have already established effective syphilis control programs that include screening of pregnant women and high-risk populations. The WHO recommends that Syphilis testing be done at the point of care when and where possible in order to maximize the number of patients who receive their results and the appropriate treatment quickly.
ABMC Chief Executive Officer Stan Cipkowski stated, "We have continued to explore additional opportunities to expand our contract manufacturing operations in fields other than drugs of abuse. Contract manufacturing is a profitable sales division for ABMC and HDS's projections for this product indicate that this will be a nice addition to ABMC's top and bottom line."
HDS President Lawrence Salvo stated, "The cooperative effort between HDS and ABMC continues to grow and expand. With the completion of our latest housing design, the EXPRESS, and worldwide patent processes, the strength of demand for HDS products has increased considerably. The relationship we have with ABMC is an important one, as the quality of our final device relies upon the quality of the component supplied to us by ABMC. Over the past years, we have come to rely upon ABMC as a company dedicated to quality, reliability and price, all of which we share as important and key elements for our success at HDS."
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid One®, Rapid TEC®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup™ products test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
About Hema Diagnostic Systems
Hema Diagnostic Systems is a rapidly growing biotechnology company involved in the development, manufacture, assembly and distribution of diagnostics targeting primary as well as orphan infectious diseases. Incorporating both rapid, Point-Of-Care test devices and a new and growing line of ELISA assays, Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are made simple to use and are highly cost effective when incorporated into Hema Diagnostic Systems' patented and patent pending delivery systems. The Rapid 1-2-3 Hema EXPRESS as well as the Rapid 1-2-3 Hema EZ® are novel delivery systems that are self contained and easy to use. HDS offers Elisa assays under HDS' QUANTIFLEXX® brand name.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2006, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
American Bio Medica Corporation
ABMC pentru fabricarea de test pentru sifilis - ABMC To Manufacture Test For Syphilis - articole medicale engleza - startsanatate